No annual revenue total was found in Filana Therapeutics, Inc.'s SEC filings.
Filana Therapeutics, Inc. (FLNA) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$32.8 million.
Revenue
—
Net income
$-90.97M
-273.7% vs prior year
Operating cash flow (TTM)
$-29.79M
+72.7% vs year-ago TTM
Free cash flow
$-32.83M
+71.9% vs prior year
EPS
$-1.88
-28.8% vs prior year
Dividend per share
None
Shares outstanding
48.31M
+0.0% vs prior year
Net cash
$121.14M
FY 2023
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FLNA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1069530
- Former names
- CASSAVA SCIENCES INC (until Feb 19, 2026); PAIN THERAPEUTICS INC (until Mar 25, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$95.4M | -$141.4M | -$106.0M | -$80.0M | -$32.9M |
| Net income | -$91.0M | -$24.3M | -$97.2M | -$76.2M | -$32.4M |
| Diluted EPS | -$1.88 | -$1.46 | — | — | — |
| Operating cash flow | -$32.3M | -$116.9M | -$82.0M | -$77.5M | -$30.2M |
| Free cash flow | -$32.8M | -$117.0M | -$82.4M | -$80.2M | -$52.4M |
| Total assets | $118.4M | $157.5M | $151.7M | $234.8M | $266.8M |
| Total liabilities | $44.0M | $11.8M | $14.2M | $7.3M | $12.9M |
| Stockholders' equity | $74.4M | $145.7M | $137.5M | $227.5M | $253.9M |
| Cash and investments | $95.5M | $128.6M | $121.1M | $201.0M | $233.4M |
| Total debt | — | — | $0 | $139,000 | $236,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 20, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 22, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Listing notice
|
Sep 18, 2026 | Sep 17, 2026 |
| 10-Q | Quarterly report | Jul 29, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 29, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 15, 2026 | Jun 11, 2026 |
All 1000 Filana Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.